Psoriasis Mouse Model (IL-23 Induced)
Perform quick efficacy tests to evaluate your novel psoriasis treatment strategies using the acute psoriasis mouse model
Psoriasis Mouse Model Key Characteristics
Preclinical psoriasis mouse models are essential tools for understanding the pathogenesis of psoriasis and evaluating the efficacy of novel therapeutic approaches ranging from topical to systemic treatments. Acute models, such as the IL-23 and Imiquimod-induced models, rapidly induce psoriasis-like symptoms, while chronic models mimic the long-term progression of the disease.
The acute psoriasis model, created by intradermal ear injections of recombinant IL-23, leads to acute skin inflammation. IL-23, a key cytokine, promotes pathogenic lymphocytes that drive keratinocyte differentiation and inflammation, hallmarks of psoriasis. This model mimics human psoriasis features, such as inflammatory cell infiltration, epidermal hyperplasia, and activation of inflammatory pathways.
✓ Rapid induction of psoriasis-like symptoms.
✓ Phenotype exhibits key psoriasis hallmarks, including inflammatory cell infiltration and epidermal hyperplasia.
✓ Suitable for testing IL-23 inhibitors and other modulators of the IL-23-induced inflammation pathway.
As a preclinical immunology CRO, InnoSer offers relevant expertise to support various skin inflammation studies including psoriasis, atopic dermatitis, contact dermatitis, and scleroderma research. In accordance, our dermatological platform allows us to investigate the efficacy of your novel investigational compound(s) in similar models, including Imiquimod-induced psoriasis, Ovalbumin or Oxazole-induced atopic dermatitis, and the Bleomycin-induced scleroderma model.
Take advantage of InnoSer’s collaborative approach to develop the most optimal study design. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo immunology drug development portfolio.
Psoriasis Mouse Model Sample Data
The IL-23 induced psoriasis mouse model represents a translationally relevant model of psoriasis, while allowing you to obtain quick efficacy data.
8-weeks old C57BL6/J mice were injected with recombinant IL-23 in right ear and with PBS (serving as within-subject control) in left ear every two days for a total of 8 days. Mice were dosed with vehicle, test treatment and positive control twice daily via oral gavage. Ear thickness increased in the IL-23 control (vehicle) group following IL-23 injection. A slight decrease in ear thickness was observed on days 4 and 6 in the positive control-treated group.
The IL-23 induced psoriasis mouse model represents a translationally relevant model of psoriasis, while allowing you to obtain quick efficacy data.
Scoring of psoriasis-like lesions following histopathology assessment reveals increase in inflammatory cell infiltration and hypergranulosis in response to IL-23 treatment. Score 0 indicates presence of such features in normal limits, while scores 2 and 3 indicate slight to moderate presence of psoriasis-like features in the tissue. Bars represent M ± SD.
The IL-23 induced psoriasis mouse model represents a translationally relevant model of psoriasis, while allowing you to obtain quick efficacy data.
H&E-stained sections of ear skin confirm psoriasis-like lesions in the IL-23 induced psoriasis mouse model. Vehicle-treated ear sections show spongiosis.
Key IL-23 Induced Mouse Model Readouts
あなたの研究を支える人々
セリーヌ・エレンス博士、免疫学研究 ディレクター
当社の免疫学研究責任者が率いる専門家チーム セリーヌ・エレンス博士が率いる専門家チームが、 セリーヌ・エレンス博士が率いる専門チームが、お客様と協力し、 最適な 研究設計を確立するお手伝いをいたします。分野への深い理解をもって貴社のリード化合物の前臨床試験をキュレーションすることは、貴社の医薬品開発を加速させるための解決策です。
ヤニック・ファントン博士、最高科学責任者
イノサーの最高科学責任者として、ヤニックはイノサーにおける全ての顧客調査を担当し、科学的・技術的な調整業務を統括している。
よくあるご質問
What is the IL-23 psoriasis mouse model?
The IL-23 psoriasis mouse model is a widely used preclinical model for studying psoriasis pathogenesis and treatment efficacy. It mimics the chronic inflammation and skin lesions seen in human psoriasis by leveraging the role of IL-23, a key cytokine in driving disease progression. Intradermal injection of IL-23 (into the ear) induces a psoriasis-like inflammatory response. IL-23 promotes Th17 cell activation, leading to increased IL-17 and IL-22 production, which drives keratinocyte proliferation and skin thickening. The model exhibits hallmark psoriasis symptoms, including epidermal hyperplasia, erythema, scaling, and immune cell infiltration.
What is the role of IL-23 in the treatment of psoriasis?
Can this model be used to study both early and chronic stages of psoriasis?
What are the timelines and deliverables for studies using this model?
- Day -3 to 0: Acclimatization, baseline measurements (ear thickness, weight, images).
- Days 0-8: Intradermal IL-23 injection (right ear, every 2 days), PBS control (left ear). Monitor inflammation (swelling, redness, scaling).
- Days 9-10: Final assessments, tissue collection.
その他の関連する免疫学マウスモデルを発見する
好奇心を持ち続けよう：さらに探求できる記事
Personalized Lymphoma CDX mouse models for preclinical oncology
In recent studies, we established and validated two new human lymphoma cell‑line–derived xenograft (CDX) models, generated from the OCI‑Ly19 (diffuse large B‑cell lymphoma, DLBCL) and REC‑1 (mantle cell lymphoma) cell lines. These models were developed in strategic...
免疫腫瘍学研究におけるマルチプレックスサイトカインおよび免疫細胞プロファイリング
メソスケール・ディスカバリー（MSD）プラットフォームは、高感度かつ多重のサイトカインプロファイリング分析システムであり、ごく微量のサンプル（わずか1μL）から複数の標的サイトカイン、ケモカイン、抗体、成長因子を同時に定量することが可能です。これにより...
膵臓癌患者由来異種移植モデル
先月11月は膵臓がん啓発月間でした。これは最も攻撃的で致死率の高いがん種の一つがもたらす課題に焦点を当てる時期です。膵臓がんは欧州で診断される全がんの約3％を占め、膵臓...
InnoSerの主要なin vitro腫瘍学サービスを探る：PD-1/PD-L1遮断アッセイ
腫瘍学における免疫チェックポイント阻害剤の創薬近年、免疫チェックポイント阻害は免疫腫瘍学における画期的な治療戦略として台頭している。プログラム細胞死1受容体（PD-1）とそのリガンドであるプログラム細胞死リガンド1（PD-L1）...
AAALAC認定
InnoSerはAAALAC認証を取得し、責任ある動物ケアと利用への取り組みを実証しています。AAALAC Internationalは、自主的な認証および評価プログラムを通じて科学における動物の適切な扱いを推進する非営利組織です。InnoSerのオランダおよびベルギー施設は、それぞれ2016年および2020年よりAAALAC認証を取得しています。AAALAC認証プログラムの詳細はこちらをご覧ください。
動物福祉
3R原則は、政策や規制の変更から新技術・手法の開発と普及に至るまで、あらゆる分野に影響を及ぼします。このためInnoSerは、これらのプロセスに対する継続的な取り組みと監視を実施しています。当社が実践する手順は、動物実験の代替・削減・改善を最大限に実現し、研究および医薬品開発におけるこれらの原則への取り組みを促進します。
info@innoserlaboratories.com